CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients
- PMID: 30196822
- DOI: 10.1016/j.jneuroim.2018.08.004
CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients
Abstract
Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data highlighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.
Keywords: CTLA-4; Multiple sclerosis; PD-1; TIM-3.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.Front Immunol. 2019 Apr 30;10:835. doi: 10.3389/fimmu.2019.00835. eCollection 2019. Front Immunol. 2019. PMID: 31134049 Free PMC article.
-
Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms.Hum Immunol. 2025 May;86(3):111298. doi: 10.1016/j.humimm.2025.111298. Epub 2025 Mar 27. Hum Immunol. 2025. PMID: 40154098
-
Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.Arthritis Rheumatol. 2018 Apr;70(4):566-577. doi: 10.1002/art.40399. Epub 2018 Mar 7. Arthritis Rheumatol. 2018. PMID: 29245183 Free PMC article.
-
The role of immune regulatory molecules in multiple sclerosis.J Neuroimmunol. 2019 Dec 15;337:577061. doi: 10.1016/j.jneuroim.2019.577061. Epub 2019 Sep 5. J Neuroimmunol. 2019. PMID: 31520791 Review.
-
Immune checkpoint inhibitors for cancer treatment.Arch Pharm Res. 2016 Nov;39(11):1577-1587. doi: 10.1007/s12272-016-0850-5. Epub 2016 Oct 21. Arch Pharm Res. 2016. PMID: 27770382 Review.
Cited by
-
Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS.Int J Mol Sci. 2022 Mar 16;23(6):3185. doi: 10.3390/ijms23063185. Int J Mol Sci. 2022. PMID: 35328606 Free PMC article.
-
Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II.Front Immunol. 2022 Jan 13;12:770402. doi: 10.3389/fimmu.2021.770402. eCollection 2021. Front Immunol. 2022. PMID: 35095844 Free PMC article.
-
Current understanding of CTLA-4: from mechanism to autoimmune diseases.Front Immunol. 2023 Jul 11;14:1198365. doi: 10.3389/fimmu.2023.1198365. eCollection 2023. Front Immunol. 2023. PMID: 37497212 Free PMC article. Review.
-
Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age.EBioMedicine. 2022 Aug;82:104179. doi: 10.1016/j.ebiom.2022.104179. Epub 2022 Jul 19. EBioMedicine. 2022. PMID: 35868128 Free PMC article.
-
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.Cells. 2025 Apr 6;14(7):552. doi: 10.3390/cells14070552. Cells. 2025. PMID: 40214505 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials